Skip to main content

Table 3 Significant prognostic factors for 5-year LRR by multivariate regression analyses

From: Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy

Variables Multivariate analyses
LRR
HR 95%CI p
1999–2007
vs. 2008–2014
1.923 1.380–2.688 < 0.001
Age ≤ 40 years old
vs. > 40 years old
2.262 1.646–3.107 < 0.001
Inner location
vs. Non-inner location
2.236 1.787–2.798 < 0.001
T2 stage
vs. T1 stage
1.419 1.061–1.898 0.018
ER/PR (−)
vs. ER and PR(+)
1.485 1.042–2.117 0.029
LVI
vs. without LVI
1.053 0.879–1.262 0. 575
Grade III
vs. Grade I and II
1.237 0.8861.726 0. 212
IDC
vs. other pathology type
0.848 0.715–1.006 0.059
Adjuvant chemotherapy
vs. non-adjuvant chemotherapy
1.429 0.951–2.147 0.086
Endocrine therapy
vs. non- Endocrine therapy
0.728 0.524–1.012 0.059
Anti-Her2 target therapy
vs. non- Anti-Her2 target therapy
0.606 0.246–1.492 0.276
  1. ER Estrogen receptor, Her2 Human epidermal growth factor receptor 2, HR Hazard ratio, IDC Invasive ductal carcinoma, LRR Locoregional recurrence, LVI Lymphovascular invasion, PR Progesterone receptor
\